ArticleAlzheimer's research & therapy2026
In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences.
Andre Mueller et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.